ENT, which causes drug-induced intrahepatic cholestasis, decreases myosin light chain 2 phosphorylation through myosin light chain kinase and results in BC dilation (Burbank et al., 2016; Sharanek et al., 2016). Here, MYL2 is linked to intrahepatic cholestasis.